Chargement en cours...
Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma
PURPOSE: To evaluate the safety and efficacy of panobinostat plus everolimus in patients with relapsed Hodgkin and non-Hodgkin lymphoma. The concept was supported by the single agent clinical activity of histone deacetylase inhibitors and mTOR inhibitors, and on the in vitro mechanism-based synergis...
Enregistré dans:
| Publié dans: | Clin Cancer Res |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4409814/ https://ncbi.nlm.nih.gov/pubmed/24097867 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-1906 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|